Biomerica INC 10-K annual reports

Biomerica, Inc. has filed an amendment to its 2026 Annual Report on Form 10-K, primarily to restate Part III items concerning directors, executive officers, corporate governance, and related matters, alongside new certifications.

Biomerica, Inc. filed its annual report for the fiscal year ended May 31, 2026, detailing a 16% revenue decline, continued operating losses, and significant concerns regarding its ability to continue as a going concern, though it secured additional financing and advanced product commercialization.

Biomerica, Inc. filed an amendment to its 2025 Annual Report, providing updated disclosures on corporate governance, executive compensation, and capital stock structure.

Biomerica, a biomedical technology company, reported a net loss of $4.97 million for fiscal year 2025, alongside a 2% decrease in net sales, while actively pursuing commercialization of its inFoods IBS and hp+detect products and implementing significant cost-cutting measures.

Biomerica's fiscal year 2024 saw a revenue increase driven by non-COVID products, alongside cost-cutting measures due to slower-than-expected product launches.